Abilify and Olmetec drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Abilify (aripiprazole) and Olmetec (olmesartan medoxomil). Common drug interactions include acute myocardial infarction among females and diabetes mellitus among males.

The phase IV clinical study analyzes what interactions people have when they take Abilify and Olmetec. It is created by eHealthMe based on reports of 33 people who take the same drugs from the FDA, and is updated regularly.

What is Abilify?

Abilify has active ingredients of aripiprazole. It is often used in depression. eHealthMe is studying from 101,454 Abilify users. Check the latest studies of Abilify.

What is Olmetec?

Olmetec has active ingredients of olmesartan medoxomil. It is often used in high blood pressure. eHealthMe is studying from 7,904 Olmetec users. Check the latest studies of Olmetec.



On Jul, 20, 2026

33 people who take Abilify and Olmetec together, and have interactions are studied.

Abilify and Olmetec drug interactions.

What are the common drug interactions of Abilify and Olmetec, by gender? *:

female:

  1. Acute myocardial infarction (acute heart attack)
  2. Cardiac failure congestive
  3. Coronary artery stenosis (narrowing of coronary artery)
  4. Malaise (a feeling of general discomfort or uneasiness)
  5. Nasopharyngitis (inflammation of the nasopharynx)
  6. Renal failure (kidney dysfunction)
  7. Alopecia (absence of hair from areas of the body)
  8. Arrhythmia (irregular heartbeat)
  9. Blood glucose increased
  10. Hypercholesterolaemia (high levels of cholesterol in the blood)

male:

  1. Diabetes mellitus (diabetes, caused by a deficiency of the pancreatic hormone insulin)
  2. Diabetic ketoacidosis (diabetic ketoacidosis (dka) is high concentrations of ketone bodies)
  3. Blood sodium decreased
  4. Blood urea decreased
  5. Renal impairment (severely reduced kidney function)
  6. Shock (a life-threatening condition with symptoms like low blood pressure, weakness, shallow breathing, cold, clammy skin)
  7. Electrocardiogram qt prolonged
  8. Liver disorder (liver diseases)
  9. Ventricular extrasystoles (premature cardiac contraction)
  10. Abdominal distension

What are the common drug interactions of Abilify and Olmetec, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

  1. Abdominal distension
  2. Decreased appetite
  3. Enterocolitis (inflammation of the digestive tract, involving enteritis of the small intestine and colitis of the colon)
  4. Extradural abscess (pus may gather between a patient's skull and his dura)
  5. Insomnia (sleeplessness)
  6. Irritability
  7. Obsessive-compulsive disorder (an anxiety disorder characterized by intrusive thoughts that produce uneasiness, apprehension, fear, or worry;)
  8. Pyrexia (fever)
  9. Vomiting

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Diabetes mellitus (diabetes, caused by a deficiency of the pancreatic hormone insulin)
  2. Diabetic ketoacidosis (diabetic ketoacidosis (dka) is high concentrations of ketone bodies)
  3. Bacteraemia (presence of bacteria in the blood)
  4. Cellulitis (infection under the skin)
  5. Pneumonia
  6. Pyrexia (fever)
  7. Seizure (abnormal excessive or synchronous neuronal activity in the brain)

50-59:

  1. Drug-induced liver injury (diseases of the liver that are caused by physician-prescribed medications)
  2. Renal disorder (kidney disease)
  3. Arrhythmia (irregular heartbeat)
  4. Hypercholesterolaemia (high levels of cholesterol in the blood)
  5. Musculoskeletal stiffness (stiffness of the body's muscles, joints, tendons, ligaments and nerves)
  6. Weight increased
  7. Electrocardiogram qt prolonged
  8. Liver disorder (liver diseases)
  9. Ventricular extrasystoles (premature cardiac contraction)
  10. Muscle rigidity (muscle stiffness)

60+:

  1. Renal failure (kidney dysfunction)
  2. Blood potassium increased
  3. Blood glucose increased
  4. Blood sodium decreased
  5. Blood urea decreased
  6. Renal impairment (severely reduced kidney function)
  7. Rhabdomyolysis (a condition in which damaged skeletal muscle tissue breaks down)
  8. Shock (a life-threatening condition with symptoms like low blood pressure, weakness, shallow breathing, cold, clammy skin)
  9. Oesophageal carcinoma (cancer tumour of oesophagus)
  10. Aspartate aminotransferase increased

What are the existing conditions these people have? *

  1. Schizophrenia (a mental disorder characterized by a breakdown of thought processes): 6 people, 18.18%
  2. Stress And Anxiety: 4 people, 12.12%
  3. Pain: 4 people, 12.12%
  4. Insomnia (sleeplessness): 4 people, 12.12%
  5. Schizoaffective Disorder (a mental disorder characterized by disordered thought): 3 people, 9.09%
  6. Mania (a state of abnormally elevated or irritable mood): 3 people, 9.09%
  7. Constipation: 3 people, 9.09%
  8. Bipolar Disorder (mood disorder): 3 people, 9.09%
  9. Osteoarthritis (a joint disease caused by cartilage loss in a joint): 2 people, 6.06%
  10. High Blood Cholesterol: 2 people, 6.06%

* Approximation only. Some reports may have incomplete information.

Do you take Abilify and Olmetec?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Abilify and Olmetec:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Abilify:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Olmetec:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Abilify and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Olmetec and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on aripiprazole and olmesartan medoxomil (the active ingredients of Abilify and Olmetec, respectively), and Abilify and Olmetec (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: